within Pharmacolibrary.Drugs.ATC.J;

model J01DH06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.00021833333333333332,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0155,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DH06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tebipenem pivoxil is an orally bioavailable prodrug of tebipenem, which is a carbapenem antibiotic used primarily for the treatment of multidrug-resistant bacterial infections, especially respiratory tract and urinary tract infections. Tebipenem pivoxil has been approved in Japan for pediatric use in infections caused by susceptible strains, but as of 2024 it is not widely approved outside Japan for routine use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in healthy adult volunteers after a single oral dose of 200 mg tebipenem pivoxil.</p><h4>References</h4><ol><li><p>Patel, G, et al., &amp; Talley, AK (2022). Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment. <i>Antimicrobial agents and chemotherapy</i> 66(5) e0240721–None. DOI:<a href=\"https://doi.org/10.1128/aac.02407-21\">10.1128/aac.02407-21</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35420493/\">https://pubmed.ncbi.nlm.nih.gov/35420493</a></p></li><li><p>Li, Z, et al., &amp; Qu, L (2021). Pharmacokinetics, Urinary Excretion, and Pharmaco-Metabolomic Study of Tebipenem Pivoxil Granules After Single Escalating Oral Dose in Healthy Chinese Volunteers. <i>Frontiers in pharmacology</i> 12 696165–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2021.696165\">10.3389/fphar.2021.696165</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34326771/\">https://pubmed.ncbi.nlm.nih.gov/34326771</a></p></li><li><p>Eckburg, PB, et al., &amp; Melnick, D (2019). Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects. <i>Antimicrobial agents and chemotherapy</i> 63(9) –. DOI:<a href=\"https://doi.org/10.1128/AAC.00618-19\">10.1128/AAC.00618-19</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31262768/\">https://pubmed.ncbi.nlm.nih.gov/31262768</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DH06;
